Back to Clinical Feed
Try:
PLOS ONEResearch HighlightsOpen Access
Identification of potential key genes that respond to capsaicin treatment in ER-positive breast cancer: An integrated analysis
03 Jun 20264 min read0 viewsJournal Feed
GIST (Key Takeaways)
- by Long Zheng, Wenjin Li, Bing Wang, Tao Wu, Hao Huang, Yongchao He, Wei Qu Capsaicin, a natural compound, has demonstrated antitumor efficacy in estrogen receptor-positive breast cancer (ER-positive BC). However, its downstream molecular targets and mechanisms remain poorly understood, particularly those linked to metabolic reprogramming and immune modulation. This study aimed to identify capsaicin-responsive genes and explore their roles in ER-positive BC progression and tumor microenvironment remodeling.
- Bioinformatic analysis was performed on the GSE64155 dataset from GEO to screen differentially expressed genes (DEGs) in capsaicin-treated ER-positive BC. Functional enrichment (GO/KEGG) and protein-protein interaction (PPI) network analyses were performed to prioritize key genes. Experimental validation included qPCR and Western blotting to assess gene and protein expression in capsaicin-treated cells.
- Clinical relevance was evaluated using TCGA expression data, survival analysis (overall survival [OS], relapse-free survival [RFS], and distant metastasis-free survival [DMFS]), and immunohistochemistry (IHC) in BC tissues. Immune cell infiltration was analyzed via the CIBERSORT algorithm. SHMT2 and GARS were identified as the most significant capsaicin-responsive genes.
Clinical Editorial
Summary
PLOS ONE (Medicine) published a clinical update in Research Highlights on 03 Jun 2026.
The item focuses on Identification of potential key genes that respond to capsaicin treatment in ER-positive breast cancer: An integrated analysis.
Review the original article for the full source wording and details.
Source Reference
Read the full original publication from the source journal or publisher link below.
Related by Condition/Drug
BMJ OpenRelated by Conditionbreast cancer
Fluorescence imaging using indocyanine green to identify sentinel lymph nodes during surgery for breast cancer (INFINITE): protocol for a hybrid effectiveness-implementation trial using a stepped-wedge cluster design
Research Highlights • 24 Jun 2026
STATRelated by Conditionbreast cancer
STAT+: Pharmalittle: We’re reading about weight loss drug spending, launch prices for medicines, and much more
Research Highlights • 25 Jun 2026
NatureRelated by Conditionbreast cancer
Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER + HER2 − breast cancer: a randomized phase 2 trial
Research Highlights • 25 Jun 2026
Endocrine NewsRelated by Conditionbreast cancer
Looking Back: Unforgettable Moments from ENDOs Past
Research Highlights • 24 Jun 2026
PLOS ONERelated by Conditionbreast cancer
Synergistic anticancer activity of antimicrobial peptide nisin and doxorubicin against breast cancer cells via modulation of membrane permeability
Research Highlights • 23 Jun 2026
PLOS ONERelated by Conditionbreast cancer
Thyroid V40 as a potential early predictor of hypothyroidism following hypofractionated locoregional breast radiotherapy
Research Highlights • 18 Jun 2026
Feed Metadata
Source
PLOS ONE (Medicine)
Category
Research Highlights
Published
03 Jun 2026
Feed Metadata
Source
PLOS ONE (Medicine)
Category
Research Highlights
Published
03 Jun 2026